aTyr Pharma
ATYR
49 hedge funds and large institutions have $50.5M invested in aTyr Pharma in 2016 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 16 increasing their positions, 11 reducing their positions, and 19 closing their positions.
45% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 19
2% less funds holding
Funds holding: 50 → 49 (-1)
10% less capital invested
Capital invested by funds: $55.8M → $50.5M (-$5.33M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.53M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.14M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$869K |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$806K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$797K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$8.42M |
| 2 |
RIM
RS Investment Management
San Francisco,
California
|
-$6.22M |
| 3 |
GCM
Gruss Capital Management
New York
|
-$2.36M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.05M |
| 5 |
JP Morgan Chase
New York
|
-$1.09M |
ATYR Hedge Fund Activity: Q2 2016 in Review
49 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q2 2016, worth a combined $50.5M — down 9.6% from $55.8M a quarter earlier.
Fund positioning in ATYR was balanced in Q2 2016: 19 funds opened new positions, 19 closed out, 16 added to existing stakes and 11 trimmed.
The largest buyer was Alyeska Investment Group, adding an estimated $1.53M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $8.42M sold.
- 49 institutional investors held aTyr Pharma (ATYR) as of Q2 2016, down from 50 in Q1 2016.
- Funds reported $50.5M of aTyr Pharma stock for Q2 2016, down 9.6% quarter-over-quarter.
- 19 funds opened new aTyr Pharma positions in Q2 2016 and 19 closed out, a net change of 0 holders.
- The largest aTyr Pharma buyer in Q2 2016 was Alyeska Investment Group, an estimated $1.53M added.
- The largest aTyr Pharma seller in Q2 2016 was Baker Bros. Advisors, an estimated $8.42M sold.
Based on aggregated 13F filings for Q2 2016.